SecBot SecBot
8-K ·Filed Mar 5, 2026

OTLK

Outlook Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago SEC0001104659-26-024189
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Traders should monitor for future FDA communications or guidance from Outlook Therapeutics regarding the regulatory pathway for ONS-5010. The lack of a clear resolution maintains significant regulatory risk, which is a key overhang on the stock despite the product's approval in Europe.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.4140
T+0 close · Mar 5, 2026 · via day close
Latest settled
+103.62%
T+60 · $0.8430
Vs SPY
+90.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 6 $0.4140entry
  2. T+1 · 8mo ago +8.21%α +7.37% · $0.4480
  3. T+5 · 8mo ago −4.83%α −3.30% · $0.3940
  4. T+20 · 8mo ago −51.45%α −49.40% · $0.2010
  5. T+60 · 6mo ago +103.62%α +90.84% · $0.8430
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics held a Type A meeting with the FDA to discuss the Complete Response Letter for its ONS-5010 (LYTENAVA) biologics license application for wet AMD. The company stated it remains committed to working with the FDA to clarify the path forward for potential approval, but no resolution or timeline was provided.

Key Facts

  • Outlook Therapeutics conducted a Type A meeting with the FDA on March 5, 2026, regarding the CRL issued on December 30, 2025 for ONS-5010/LYTENAVA.
  • The meeting focused on the FDA's concern about 'substantial evidence of effectiveness' for the BLA.
  • The company reiterated that NORSE TWO met primary and key secondary endpoints and that NORSE EIGHT and other data support confirmatory evidence of efficacy and safety.
  • No decision, resolution, or timeline for approval was announced; the company will continue discussions with the FDA.
  • LYTENAVA is already approved in the EU and UK for wet AMD and has launched in Germany, Austria, and the UK.

Financial Impact

No immediate financial impact disclosed. The outcome of the FDA review will determine future revenue potential for ONS-5010 in the U.S. market.

revenuecashFlowmarketCap

Risk Factors

  • FDA may require an additional clinical trial, which would significantly delay U.S. approval and increase costs.
  • Continued regulatory uncertainty could pressure the stock price and limit investor interest.
  • Failure to gain U.S. approval would eliminate the primary growth catalyst for the company.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-024189
Document: tm268164d1_ex99-1.htm0001104659-26-024189
Document: 0001104659-26-024189-index-headers.html0001104659-26-024189
Document: 0001104659-26-024189-index.html0001104659-26-024189
Document: 0001104659-26-024189.txt0001104659-26-024189

Track record

37 reports on OTLK

Performance horizon

13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026